Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DART 1: Once-Daily ddI-EC/3TC/EFV in HIV
NCT00116415Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2002
- Primary completion
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of didanosine in human immunodeficiency virus infection (HIV), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of patients with plasma HIV-1 RNA <400 copies/mL at 48 weeks. Started Mar 2002; status: completed.
02
Drugs
didanosine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00116415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116415.